Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.

Abstract:

:Twenty-nine patients with non-Hodgkin's lymphoma received a single subcutaneous injection of 6 mg pegfilgrastim approximately 24 h after the start of CHOP chemotherapy. The safety of pegfilgrastim in this patient population was determined by reports of adverse events. The pharmacokinetics of pegfilgrastim were characterized and the duration of grade 4 neutropenia, time to absolute neutrophil count (ANC) recovery to > or = 2.0 x 10(9)/l, neutrophil nadir, and incidence of febrile neutropenia were determined in the first 21-day chemotherapy cycle. The incidence of grade 4 neutropenia in cycle 1 was 43% with a mean (SD) duration of grade 4 neutropenia value of 1.0 (1.4) day. No apparent relationship between the duration of grade 4 neutropenia and body weight was observed. The median [quartiles] time to ANC recovery was 10 [9, 11] days. The incidence of febrile neutropenia was 11%. No unexpected adverse events were reported and no patient developed antibodies to pegfilgrastim. Serum concentration of pegfilgrastim reached a maximum (median [quartiles]) of 128 [58, 159] ng/ml at approximately 24 h after administration, and was followed by a second smaller peak (median [quartiles]) of 10.6 [3.0, 20.5] ng/ml at the time of the neutrophil nadir. After the second peak, concentration of pegfilgrastim declined linearly with a median terminal half-life of approximately 42 h.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

George S,Yunus F,Case D,Yang BB,Hackett J,Shogan JE,Meza LA,Neumann TA,Liang BC

doi

10.1080/1042819031000063462

keywords:

subject

Has Abstract

pub_date

2003-10-01 00:00:00

pages

1691-6

issue

10

eissn

1042-8194

issn

1029-2403

journal_volume

44

pub_type

杂志文章,多中心研究
  • Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease.

    abstract::There is increasing evidence for an interaction between acute leukemia cells and the microenvironment of the bone marrow. Blast cells from cases of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) bind to cellular and extracellular matrix components of the bone marrow stroma. In AML, adhesion to str...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199509064917

    authors: Bradstock KF,Gottlieb DJ

    更新日期:1995-06-01 00:00:00

  • Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma.

    abstract::The human germinal center-associated lymphoma (HGAL) gene has prognostic value in diffuse large B-cell lymphoma, and expression of its cognate protein is germinal center-specific. A previous study had suggested that HGAL protein expression might also be related to the outcome in patients with Hodgkin lymphoma (HL). Th...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903242628

    authors: Azambuja D,Lossos IS,Biasoli I,Morais JC,Britto L,Scheliga A,Pulcheri W,Natkunam Y,Spector N

    更新日期:2009-11-01 00:00:00

  • Allergic reactions associated with pegaspargase in adults.

    abstract::One of the severe toxicities of pegaspargase (PEG) is the development of allergic reactions. This study retrospectively assessed 311 PEG doses administered to 139 acute lymphoblastic leukemia patients from May 1, 2008 to July 30, 2014 for allergic reactions based on the Common Terminology Criteria for Adverse Events (...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1105369

    authors: Chang A,Kim M,Seyer M,Patel S

    更新日期:2016-07-01 00:00:00

  • High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.

    abstract::Nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) is a rare variant of Hodgkin's lymphoma (HL) in children. Since specific immunohistochemical staining has become available, NLPHL can be separated from classical Hodgkin's lymphoma (cHL) more accurately. Scarce information is available about pediatric NLPHL tre...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600573291

    authors: van Grotel M,Lam KH,de Man R,Beishuizen A,Pieters R,van den Heuvel-Eibrink MM

    更新日期:2006-08-01 00:00:00

  • Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.

    abstract::The prognostic significance of rare BCR-ABL1 transcripts is uncertain in the tyrosine kinase inhibitor (TKI) era. In this retrospective study, 40 (1.7%) patients with rare BCR-ABL1 transcripts were identified from a cohort of 2331 chronic myeloid leukemia (CML) patients; 4 types of rare transcripts were identified, in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1607329

    authors: Xue M,Wang Q,Huo L,Wen L,Yang X,Wu Q,Pan J,Cen J,Ruan C,Wu D,Chen S

    更新日期:2019-12-01 00:00:00

  • Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.

    abstract::Myocyte enhancer factor 2C (MEF2C) encodes a transcription factor which is ectopically expressed in T-cell acute lymphoblastic leukemia (T-ALL) cell lines, deregulated directly by ectopically expressed homeodomain protein NKX2-5 or by loss of promoter regions via del(5)(q14). Here, we analyzed the MEF2C 5'-region, thu...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.537003

    authors: Nagel S,Venturini L,Meyer C,Kaufmann M,Scherr M,Drexler HG,Macleod RA

    更新日期:2011-02-01 00:00:00

  • Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature.

    abstract::Isochromosome 17q [i(17q)] is frequently observed in the blast crisis (BC) of chronic myelogenous leukemia (CML). It has been suggested that this chromosome abnormality is associated with special hematological characteristics of the BC, but the information on this subject is scarce. The clinical, hematological and cyt...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009060321

    authors: Hernández-Boluda JC,Cervantes F,Costa D,Carrió A,Montserrat E

    更新日期:2000-06-01 00:00:00

  • Long noncoding RNA LINC00467 facilitates the progression of acute myeloid leukemia by targeting the miR-339/SKI pathway.

    abstract::A growing body of evidence indicates that long non-coding RNA (lncRNA) is involved in the development and progression of many diseases. It has been reported that lncRNA LINC00467 is disregulated in multiple tumors, while its role in acute myeloid leukemia (AML) is still unknown. Here, we find that LINC00467 expression...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1832667

    authors: Lu J,Wu X,Wang L,Li T,Sun L

    更新日期:2020-10-15 00:00:00

  • Analysis of chromosome 6q deletion in EBV-associated NK cell leukaemia/lymphoma.

    abstract::Deletions involving chromosome 6q have been reported in a number of human cancers such as ovarian and breast tumours as well as haematopoietic malignancies. It seems that this region might contain tumour-suppressor genes. Putative natural killer cell lymphomas/leukaemias (NKLL) represent a group of recently characteri...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290006062

    authors: Ohshima K,Haraokaa S,Ishihara S,Ohgami A,Yoshioka S,Suzumiya J,Kikuchi M

    更新日期:2002-02-01 00:00:00

  • Parvovirus-B19 infection preceding acute myeloid leukemia with orbital granulocytic sarcoma.

    abstract::We report here an unusual presentation of acute nonlymphoblastic leukemia with ocular granulocytic sarcoma who was firstly diagnosed iron deficiency anemia and acute parvovirus infection induced erythroid hypoplasia. To our knowledge this is the first paper of acute myeloblastic leukemia (AML) with granulocytic sarcom...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000016168

    authors: Fisgin T,Yarali N,Duru F,Kara A

    更新日期:2002-10-01 00:00:00

  • Epstein-Barr virus (EBV)-induced B-cell proliferative disorder after chemotherapy in a patient with hemophagocytic lymphohistiocytosis with associated EBV-induced T-cell proliferation.

    abstract::We report a case of Epstein-Barr virus (EBV)-associated lymphoproliferative disorder (LPD) which developed after chemotherapy for hemophagocytic lymphohistiocytosis (HLH), who had no history of immunodeficiency or familial X-linked LPD. In HLH, the presence of EBV in T-cells was confirmed by a combination of in situ h...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009058512

    authors: Suzumiya J,Ohshima K,Kanda M,Kumagawa M,Nagano M,Hirata M,Nawa Y,Tamura K,Kikuchi M

    更新日期:2000-05-01 00:00:00

  • Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases.

    abstract::Plasmablastic lymphoma (PBL) is a recently described type of non-Hodgkin's lymphoma (NHL) that occurs in up to 3% of patients with HIV infection. Although the clinical-pathological features of several patients with HIV-associated plasmablastic lymphoma are documented, detailed description of clinical outcome is limite...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190410001697395

    authors: Lester R,Li C,Phillips P,Shenkier TN,Gascoyne RD,Galbraith PF,Vickars LM,Leitch HA

    更新日期:2004-09-01 00:00:00

  • Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells.

    abstract::Bone marrow mesenchymal stromal cells (MSCs) can rescue acute lymphoblastic leukemia (ALL) cells from L-asparaginase by replenishing the depleted asparagine. As both vincristine (VCR) and imatinib mesylate (IM) can inhibit MSCs' proliferation, we hypothesized that these drugs might reduce the niche support of MSCs to ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903406798

    authors: Fung KL,Liang RH,Chan GC

    更新日期:2010-03-01 00:00:00

  • A type of rat hepatosplenic gamma-delta (gammadalta) T-cell lymphoma developed after injections with hepatocyte growth factor (HGF) oligonucleotides, which was rejected by surviving syngeneic spleen graft.

    abstract::The transduction of exogenous hepatocyte growth factor (HGF) genes to spleen T lymphocytes and the immune effects of syngeneic spleen graft on spleen lymphoma cells were studied in LEW/Sea rats. Three different systems were designed. (1) Six female rats and six male rats received irradiated spleen graft and were follo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000057360

    authors: Nakatsuji T

    更新日期:2003-01-01 00:00:00

  • Autologous transplantation with tumor-free graft: a model for multiple myeloma patients.

    abstract::The importance of obtaining a tumor-free graft for autologous transplantation in cancer patients has been debated extensively in the last decade and is still unresolved largely because it is believed that relapse is more likely to originate from the host and not from the graft. This is in spite of recent indications t...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199609054822

    authors: Gazitt Y,Reading CL

    更新日期:1996-10-01 00:00:00

  • Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I.

    abstract::Therapy with an immunotoxin, anti-Tac(Fv)-PE38, which is a conjugate of the variable domains of an anti-Tac monoclonal antibody and Pseudomonas exotoxin, was reported to be useful for adult T cell leukemia (ATL) patients but a considerable amount of the immunotoxin is needed for the therapy and some side effects were ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290017042

    authors: Ohno N,Kreitman RJ,Saito T,Masamoto I,Uozumi K,Hanada S,Takeuchi S,Furukawa T,Sumizawa T,Arima T,Akiyama S

    更新日期:2002-04-01 00:00:00

  • Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.

    abstract::Hematologic malignancies are predominantly treated with chemotherapy or a combination of chemotherapy with monoclonal antibodies. Current treatment regimens often are not satisfactory due to severe side effects and a substantial proportion of relapsed patients. This has prompted the development of better tolerated and...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190902943077

    authors: Nagorsen D,Bargou R,Ruttinger D,Kufer P,Baeuerle PA,Zugmaier G

    更新日期:2009-06-01 00:00:00

  • Risk factors for the development of atrial fibrillation on ibrutinib treatment.

    abstract::Ibrutinib increases the risk of atrial fibrillation (AF), but the associated risk factors are not clearly defined. We performed retrospective review of ibrutinib-treated patients in a large academic practice to identify risk factors for new-onset AF. Variables with p-values <.05 in logrank analysis were included as pa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1533129

    authors: Lentz R,Feinglass J,Ma S,Akhter N

    更新日期:2019-06-01 00:00:00

  • BCR/ABL transcripts and leukemia phenotype: an unsolved puzzle.

    abstract::The Philadelphia chromosome, arising as a consequence of the t(9;22) translocation, is one of the most frequent and certainly the most known cytogenetic abnormality present in human hematological malignancies. Unlike the vast majority of the other translocations, its presence is not restricted to a specific leukemia p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709051777

    authors: Saglio G,Pane F,Martinelli G,Guerrasio A

    更新日期:1997-07-01 00:00:00

  • Rearrangements of the BCL6 gene and chromosome aberrations affecting 3q27 in 54 patients with non-Hodgkin's lymphoma.

    abstract::Chromosome aberrations affecting 3q27 are among the most frequent non-random abnormalities in non-Hodgkin's lymphomas (NHL), especially the diffuse, large cell type. Recently, an association between BCL6 rearrangement and frequent extranodal lesions, rare bone marrow infiltration and a favorable clinical outcome was r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709059687

    authors: Ohshima A,Miura I,Hashimoto K,Takahashi N,Utsumi S,Nimura T,Saito M,Miki T,Hirosawa S,Miura AB

    更新日期:1997-10-01 00:00:00

  • Chemotherapy-related changes in central nervous system phospholipids and neurocognitive function in childhood acute lymphoblastic leukemia.

    abstract::Long-term survivors of childhood leukemia are at risk for neurocognitive impairment, although the neurophysiological basis is not well understood. The purpose of this study was to explore associations between changes in cerebrospinal fluid (CSF) phospholipids and neurocognitive function in children undergoing chemothe...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.717080

    authors: Krull KR,Hockenberry MJ,Miketova P,Carey M,Moore IM

    更新日期:2013-03-01 00:00:00

  • Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification.

    abstract::The purpose of this study was to better define the clinical features and natural history of peripheral T-cell lymphomas (PTCL) entities included in the Revised European American lymphoma (REAL) classification. Cases of PTCL were retrieved from the records of the Department of Pathology and classified according to the ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000030054

    authors: Arrowsmith ER,Macon WR,Kinney MC,Stein RS,Goodman SA,Morgan DS,Flexner JM,Cousar JB,Jagasia MH,McCurley TL,Greer JP

    更新日期:2003-02-01 00:00:00

  • Biochemical modulation of arabinosylcytosine for therapy of leukemias.

    abstract::Analysis of different ribonucleotide reductase inhibitors to modulate arabinosylcytosine (ara-C) metabolism suggested that pretreatment with arabinosyl-2-fluoroadenine (F-ara-A) significantly potentiated the rate of ara-CTP (5'-triphosphate of ara-C) accumulation in both quiescent lymphocytes (p = 0.046) and in cyclin...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199309149122

    authors: Gandhi V,Estey E,Keating MJ,Plunkett W

    更新日期:1993-01-01 00:00:00

  • Internal tandem duplications of Flt3 gene (Flt3/ITD) predicts a poor post-remission outcome in adult patients with acute non-promyelocytic leukemia.

    abstract::Despite progress in AML therapy, most patients eventually relapse, even the ones with normal or favorable karyotype. Since survival is poor once relapse occurs, new genetic tools above karyotype at diagnosis are needed to predict leukemia free survival. Recently, Flt3/ITD has been reported as an independent marker for...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000151851

    authors: Ciolli S,Vannucchi AM,Leoni F,Nozzoli C,Longo G,Salati A,Pancrazzi A,Bianchi L,Gigli F,Bosi A

    更新日期:2004-01-01 00:00:00

  • Pharmacokinetic self-potentiation of idarubicin by induction of anthracycline carbonyl reducing enzymes.

    abstract::Severe myelosuppression is one of the major adverse effects of Idarubicin (IDA). Especially, after two sequential therapy courses, IDA showed a stronger myelosuppression than after the first course. IDA was metabolized in liver by carbonyl reducing enzymes (CRE) to its 13-OH metabolite, idarubicinol(IDAol),which is mo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190801947526

    authors: Yamashita T,Fukushima T,Ueda T

    更新日期:2008-04-01 00:00:00

  • Systemic mast cell disease with marrow and splenic involvement associated with chronic myelomonocytic leukemia.

    abstract::Systemic mast cell disease (SMCD) has a highly variable clinical expression and course. That SMCD is associated with hematologic disorders has been widely described. We report an unusual case of systemic mast cell disease and concurrent chronic myelomonocytic leukemia in a 60 year old male. ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909167403

    authors: Smith JD,Lazarchick J

    更新日期:1999-01-01 00:00:00

  • Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.

    abstract::Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymph...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190210178

    authors: Perz J,Topaly J,Fruehauf S,Hensel M,Ho AD

    更新日期:2002-01-01 00:00:00

  • New insights into the regulation of ICAM-1 gene expression.

    abstract::Cell-cell adhesion is critical in the generation of effective immune responses and is dependent upon the expression of a variety of cell surface receptors. Intercellular adhesion molecule-1 (ICAM-1; CD54) is an inducible cell surface glycoprotein expressed at a low level on a subpopulation of hematopoietic cells, vasc...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199609051611

    authors: Ohh M,Takei F

    更新日期:1996-01-01 00:00:00

  • Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction.

    abstract::We report a 50-year-old patient with idiopathic hypereosinophilic syndrome with trisomy 8 who experienced a complete and durable hematological and cytogenetic remission with low-dose imatinib therapy. He also had a significant reversal of cardiac dysfunction with a reduction in cardiac hypertrophy, resolution of peric...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500220514

    authors: Onitilo AA,Kio EA,Singh AK,Lazarchick J

    更新日期:2005-11-01 00:00:00

  • An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.

    abstract::Lenalidomide is a backbone agent in the treatment of multiple myeloma, but dose adjustment is required for those with renal impairment (RI). We evaluated the pharmacokinetics (PK) and safety of lenalidomide and dexamethasone as frontline pre-transplant induction, with doses adjusted at start of each cycle based on cre...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1747064

    authors: Chen CI,Cao Y,Trudel S,Reece DE,Kukreti V,Tiedemann R,Prica A,Paul H,Le LW,Levina O,Kakar S,Lau A,Chen H,Chen E

    更新日期:2020-08-01 00:00:00